The Role of Drug Metabolism in Drug Discovery

Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad

Volumn , Issue , 2010, Pages 91-176

  Bohnert, Tonika ^a   Gan, Liang Shang ^a  

^a BIOGEN   (United States)

Author keywords

Drug metabolism role in drug discovery; Drug drug interactions (DDIs) and drug metabolizing enzymes and transporters; Metabolite identification and reactive intermediates

Indexed keywords

EID: 79959433139     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470538951.ch5     Document Type: Chapter

References (404)

1. Abdel-Rahman S, Kauffman R. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 2004; 44: 111-136.
2. Abdel-Razzak Z, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-715.
3. Abelo A, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28 (8): 966-972.
4. Aming Y, Haining RL. Drug Metab Dispos 2001; 29 (11): 1514-1520.
5. Anders M, Dekant W, Vamvakas S. Glutathione-dependent toxicity. Xenobiotica 1992; 22 (9/10): 1135-1145.
6. Anderson R, Kudlacek P, Clemens D. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109 (1-3): 53-67.
7. Andersson T, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38 (2): 131-137.
8. Andrews E, et al. Synthesis and pharmacological profile of two novel heterocyclic chromanols, CP-80,798 and CP-85,958, as potent LTD4 receptor antagonists. Bioorg Med Chem Lett 1995; 5 (13): 1365-1370.
9. Argoti D, et al. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol 2005; 18: 1537-1544.
10. Arnold R, Slack J, Straubinger R. Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B Anal Technol Biomed Life Sci 2004; 808 (2): 141-152.
11. Austin N, et al. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro / in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001; 31 (8-9): 677-686.
12. Ayrton A, Morgan P. Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 2008; 38 (7/8): 676-708.
13. Bachmann K. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 2006; 7: 1-14.
14. Bachmann K, Lewis J. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacotherapy 2005; 39: 1064-1072.
15. Bailey M, Dickinson R. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 2003; 145 (2): 117-137.
16. Bailey D, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46 (46): 101-110.
17. Baillie T, Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008; 21 (1): 129-137.
18. Baillie T, et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002; 182: 188-196.
19. Balani S, et al. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr Topics Med Chem 2005; 5: 1033-1038.
20. Balayssac D, et al. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156: 319-329.
21. Baranczewski P, et al. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep 2006a; 58: 341-352.
22. Baranczewski P, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006b; 58: 453-472.
23. Barter Z, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
24. Barza M. Imipenem/cilastatin. Eur J Clin Microbiol 1984; 3 (5): 453-455.
25. Benet L, Hoener B-A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71 (3): 115-121.
26. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 2008; 23 (6): 854-859.
27. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-485.
28. Bertelsen K, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31 (3): 289-293.
29. Blanchard N, et al. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. EurJ Pharm Sci 2004; 23: 189-199.
30. Boelsterli U, Hsiao C-J. The heterozygous Sod2(+/-) mouse: modeling the mitochondrial role in drug toxicity. Drug Discovery Today 2008; 13 (21/22): 982-988.
31. Bogaards J, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 30 (12): 1131-1152.
32. Born S, et al. Synthesis and reactivity of coumarin 3,4-epoxide. Drug Metab Dispos 1997; 25 (11): 1318-1324.
33. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245 (6): R768-R775.
34. Brown C, Brown J, Coleman M. How drug metabolism influences treatment outcomes. Expert Opin Drug Metab Toxicol 2007; 3 (6): 913-915.
35. Brown H, et al. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005; 60 (5): 508-518.
36. Brown H, et al. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP. Clin Pharmacokinet 2006; 45 (10): 1035-1050.
37. Brown H, Griffin M, Houston J. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007; 35 (2): 293-301.
38. Burkhart C, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001; 132 (3): 623-630.
39. Campiani G, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002; 8 (8): 615-657.
40. Castro-Perez J. Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discovery Today 2007; 12 (5/6): 249-256.
41. Catapano A. Ezetimibe: a selective inhibitor of cholesterol absorption. Eur Heart J Suppl 2001; 3: E6-E10.
42. Chambers R, et al. Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. Bioorg Med Chem Lett 1999; 9 (18): 2773-2778.
43. Chandra P, Brouwer K. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004; 21 (5): 719-735.
44. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006; 5.
45. Chen Y, et al. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 2005; 314 (3): 1125-1133.
46. Chen Y, Monshouwer M, Fitch W. Analytical tools and approaches for metabolite identification in early drug discovery. Pharm Res 2007; 24 (2): 248-257.
47. Cheung C, Gonzalez F. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008; 327 (2): 288-299.
48. Chiba M, et al. P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spec. Drug Metab Dispos 2001; 29 (1): 1-3.
49. Chien J, et al. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006; 34 (7): 1208-1219.
50. Christensen H, et al. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 2006; 95 (12): 2778-2787.
51. Clarke C, Haselden J. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol Pathol 2008; 36: 140-147.
52. Cooper A, Pinto J. Cysteine S-conjugate beta-lyases. Amino Acids 2006; 30 (1): 1-15.
53. Cooper A, Bruschi S, Anders M. Toxic, halogenated cysteine S-conjugates and targeting of mitochondrial enzymes of energy metabolism. Biochem Pharmacol 2002; 64 (4): 553-564.
54. Cotreau M, Von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44 (1): 33-60.
55. Cresteil T, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002; 30 (4): 438-445.
56. Crewe H, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34 (3): 262-265.
57. Cribb AE, et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 2006; 15 (3): 551-558.
58. Cvetkovic R, Goa K. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63 (8): 769-802.
59. Dai D, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11 (7): 597-607.
60. Dalvie D, et al. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 2002; 15 (3): 269-299.
61. Davis-Bruno K, Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Biol Interact 2006; 19: 1561-1563.
62. De Buck S, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007; 35 (4): 649-659.
63. DeBuske L. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Safety 2005; 28 (9): 789-801.
64. De Graaf I, et al. Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism. Drug Metab Dispos 2002; 30 (10): 1129-1136.
65. Dekant W. Biosynthesis of toxic glutathione conjugates from halogenated alkenes. Toxicol Lett 2003; 144 (1): 49-54.
66. Dekant W, Vamvakas S, Anders M. Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway. Adv Pharmacol 1994; 27: 115-162.
67. Delbressine L, et al. On the formation of carbamate glucuronides. Xenobiotica 1990; 20 (1): 133-134.
68. Desta Z, et al. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J Pharmacol Exp Ther 2001; 298 (2): 508-520.
69. DeVane C. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 2002; 36 (3): 5-21.
70. Dickinson P, Taylor G. Route dependent pulmonary first-pass metabolism of a series of biphenylacetic acid esters in rats. Eur J Pharm Sci 1998; 6 (1): 11-18.
71. Dieckhaus C, et al. A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab Dispos 2000; 28 (7): 814-822.
72. Doherty E, et al. 4-Aminopyrimidine tetrahydronaphthols: a series of novel vanilloid receptor-1 antagonists with improved solubility properties. Bioorg Med Chem Lett 2008; 18: 1830-1834.
73. Dunne A, O'Hara T, Devane J. Level A in vivo-in vitro correlation: nonlinear models and statistical methodology. J Pharm Sci 1997; 86 (11): 1245-1249.
74. Duret C, et al. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 2006; 70 (1): 329-339.
75. Dvorak Z, et al. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol 2003; 64 (1): 160-169.
76. Edwards R, et al. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 1994; 15 (5): 829-836.
77. Enders C, et al. The role of transporters in drug interactions. Eur J Pharm Sci 2006; 27: 501-517.
78. Erve J. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin Drug Metab Toxicol 2006; 2 (6): 923-946.
79. Evans D, et al. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004; 17: 3-16.
80. Fagerholm U. Prediction of human pharmacokinetics -evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 2007a; 59: 803-828.
81. Fagerholm U. Prediction of human pharmacokinetics -improving microsome-based predictions of hepatic metabolic clearance. J Pharm Pharmacol 2007b; 59: 1427-1431.
82. Fahmi OBS, et al. Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008; 36 (9): 1971-1974.
83. Fang H-L, et al. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J Pharmacol Exp Ther 2007; 323 (2): 586-598.
84. Felmlee M, et al. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008; 36 (2): 435-441.
85. Feng M, et al. Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 2000; 17 (4): 410-418.
86. Fisher M, et al. Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 2002; 30 (10): 1087-1093.
87. Floyd D, et al. Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. J Med Chem 1992; 35 (4): 756-772.
88. Fontana E, Dansette P, Poli S. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005; 6: 413-454.
89. Fowler S, Zhang H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 2008; 10 (2): 410-424.
90. Franconi F, et al. Gender differences in drug responses. Pharmacol Res 2007; 55: 81-95.
91. Franklin M, Hathaway L. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab Dispos 2008; 36 (12): 2539-2546.
92. Frantz C, et al. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 1995; 16 (2): 367-373.
93. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000; 38 (6): 493-504.
94. Funk C. The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 2008; 4 (4): 363-379.
95. Fura A. Role of pharmacologically active metabolites in drug discovery and development. Drug Discovery Tech 2006; 11 (3/4): 133-142.
96. Galetin A. Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo. Curr Drug Metab 2007; 8 (7): 643-644.
97. Galetin A, et al. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006; 34 (1): 166-175.
98. Gao H, et al. Method for rapid metabolite profiling of drug candidates in fresh hepatocytes using liquid chromatography coupled with a hybrid quadrupole linear ion trap. Rapid Commun in Mass Spec 2007; 21: 3683-3693.
99. Gardner I, et al. Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 1995; 25 (2): 185-197.
100. Gerntholtz T, et al. The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries. Eur J Clin Pharmacol 2004; 60 (3): 143-148.
101. Gomez-Lechon M, Castell J, Donato M. Hepatocytes -the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chemico-Biol Interactions 2007; 168: 30-50.
102. Gonzalez F. CYP3A4 and pregnane X receptor humanized mice. J Biochem Mol Toxicol 2007; 21 (4): 158-162.
103. Gonzalez F, Yu A-M. Cytochrome P450 expression and regulation in CYP3A4/ CYP2D6 double transgenic humanized mice. Annu Rev Pharmacol Toxicol 2006; 46: 41-64.
104. Gorrod J, Whittlesea C, Lam S. Biological Reactive Intermediates IV, Witmer C, editor. 1990, New York: Plenum Press, 657-664.
105. Graham M, et al. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997; 40 (1): 1-10.
106. Greenblatt D, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000; 67 (4): 335-341.
107. Grime K, Riley R. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006; 7: 251-264.
108. Grimm SW, et al. The conduct of in vitro studies to address time-dependent inhibition of drug metabolising enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America (PhRMA). Drug Metab Dispos 2009; 37(7): 1355-1370.
109. Guengerich F. Uncommon P450-catalyzed reactions. Curr Drug Metab 2001; 2: 93-115.
110. Guengerich F. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006a; 8 (1): E101-E111.
111. Guengerich F. Safety assessment of stable drug metabolites. Chem Res Toxicol 2006b; 19 (12): 1559-1560.
112. Guengerich F, MacDonald J. Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 2007; 20: 344-369.
113. Guo Z, et al. Age-and gender-related variations in the activities of drug-metabolizing and antioxidant enzymes in the white-footed mouse (Peromyscus leucopus. Growth Dev Aging 1993; 57 (2): 85-100.
114. Hakooz N, et al. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 2006; 23 (3): 533-539.
115. Hallifax D, Houston J. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos 2006; 34: 1829-1836.
116. Hallifax D, Houston J. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos 2007; 35 (8): 1325-1332.
117. Hamberg A, et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81 (4): 529-616.
118. Harper T, Brassil P. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 2008; 10 (1): 200-207.
119. Harrigan J, et al. Tissue specific induction of cytochrome P450 (CYP) 1A1 and 1B1 in rat liver and lung following in vitro (tissue slice) and in vivo exposure to benzo(a) pyrene. Toxicol In Vitro 2006; 20: 426-438.
120. Harris R, Benet L, Schwartz J. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50 (2): 222-239.
121. Hein D, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 29-42.
122. Hermann M, et al. Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. Curr Drug Metab 2006; 7: 265-271.
123. Hernandez-Martinez N, et al. Tissue-specific induction of the carcinogen-inducible cytochrome P450 isoforms in the gastrointestinal tract. Environ Toxicol Pharmacol 2007; 24 (3): 297-303.
124. Hewitt N, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007a; 39: 159-234.
125. Hewitt N, de Kanter R, LeCluyse E. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry -do they comply with FDA recommendations ? Chemico-Biol Interactions 2007b; 168: 51-65.
126. Hewitt N, LeCluyse E, Ferguson S. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007c; 37 (10/11): 1196-1224.
127. Higashikawa F, et al. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 1999; 51: 67-72.
128. Hinson J. Reactive metabolites of phenacetin and acetaminophen: a review. Environ Health Persp 1983; 49: 71-79.
129. Hollenberg P, Kent U, Bumpus N. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 2008; 21: 189-205.
130. Hop C, Chen Y, Yu L. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun Mass Spectrom 2005; 19 (21): 3139-3142.
131. Houston J, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003; 35 (4): 393-415.
132. Houston J, Kenworthy K. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 2000; 28 (3): 246-254.
133. Humphreys W, Unger S. Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res Toxicol 2006; 19: 1564-1569.
134. Huang J, Oie S. Hepatic elimination of drugs with concentration-dependent serum protein binding. J Pharmacokinet Biopharm 1984; 12 (1): 67-81.
135. Huang C, et al. Projection of exposure and efficacious dose prior to first-in-human studies: How successful have we been? Pharm Res 2008; 25 (4): 713-726.
136. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44 (2): 275-283.
137. Ioannides C, editor. Enzyme Systems that Metabolise Drugs and Other Xenobiotics, 1st ed. Vol. 1. New York: John Wiley & Sons, 2002.
138. Ishiguro N, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006; 34 (7): 1109-1115.
139. Isin E, Guengerich F. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta 2006a; 1770: 314-329.
140. Isin E, Guengerich F. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 2006b; 281 (14): 9127-9136.
141. Isoherranen N, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32 (10): 1121-1131.
142. Ito K, Houston J. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005; 22 (1): 103-112.
143. Ito K, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Annu Rev Pharmacol Toxicol 1998a; 38: 461-499.
144. Ito K, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998b; 50 (3): 387-411.
145. Iwatsubo T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73 (2): 147-171.
146. Izzo A. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42 (3): 139-148.
147. James L, Mayeux P, Hinson J. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003; 31 (12): 1499-1506.
148. Jewell WT, Miller MG. Comparison of human and rat metabolism of molinate in liver microsomes and slices. Drug Metab Dispos 1999; 27 (7): 842-847.
149. Jin S, Liu H. Gender-related differences in metabolism of the enantiomers of trans tramadol and trans O-demethyltramadol in rat liver microsomes. Yao Xue Xue Bao 2004; 39 (8): 581-585.
150. Jolivette L, Ekins S. Methods for predicting human drug metabolism. Adv Clin Chem 2007; 43: 131-176.
151. Joshi G. Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain. Curr Opin Investig Drugs 2008; 9 (7): 786-799.
152. Ju C, Uetrecht J. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367-377.
153. Kaji H, Kume T. Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetic acid (TA-1801A). Drug Metab Pharmacokinet 2005; 20 (3): 212-218.
154. Kalgutkar A, Soglia J. Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 2005; 1 (1): 91-142.
155. Kalgutkar A, et al. A comprehensive listing of bioactivation pathways of organic functional grou. Curr Drug Metab 2005a; 6: 161-225.
156. Kalgutkar A, et al. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 2005b; 33 (2): 243-253.
157. Kalgutkar A, Obach R, Maurer T. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007; 8 (5): 407-447.
158. Kalvaas J, et al. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro. Data Drug Metab Dispos 2001; 29 (10): 1332-1336.
159. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73 (1): 67-74.
160. Kane RE, Li AP, Kaminski DR. Sulfation and glucuronidation of acetaminophen by human hepatocytes cultured on Matrigel and type 1 collagen reproduces conjugation in vivo. Drug Metab Dispos 1995; 23 (3): 303-307.
161. Kapetanovic I, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26 (11): 1089-1095.
162. Katoh M, et al. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2006; 96 (2): 428-437.
163. Katoh M, et al. Chimeric mice with humanized liver. Toxicology 2008; 245: 9-17.
164. Kent UM, Jushchhyshyn M, Hollenberg P. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2001; 2 (3): 215-243.
165. Kent U, et al. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 2006; 19 (2): 279-287.
166. Khaliq Y, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodefi-ciency virus. Clin Pharm Ther 2000; 68: 637-646.
167. Kharasch ED, et al. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. Toxicol Appl Pharmacol 1999; 160: 49-59.
168. Kilicarslan T, et al. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos 2001; 29 (4): 460-465.
169. Kinobe RT, et al. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18 (12): 1868-1875.
170. Klieber S, et al. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 2008; 36 (5): 851-862.
171. Ko Y, et al. Prescribers'knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Safety 2008; 31 (6): 525-536.
172. Koenigs L, et al. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 1999; 38 (8): 2312-2319.
173. Koudriakova T, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26 (6): 552-561.
174. Kramer M, Tracy T. Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol 2008; 4 (5): 591-603.
175. Kumar S, et al. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr Opin Drug Discovery Dev 2008; 11 (1): 43-52.
176. Kunze KL, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006; 34 (4): 583-590.
177. Kuperman A, et al. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 2001; 29 (11): 1403-1409.
178. Lalovic B, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79 (5): 461-479.
179. Lam J, Benet L. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004; 32 (11): 1311-1316.
180. Lau Y, et al. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004; 308 (3): 1045-1050.
181. Lau Y, et al. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006; 316 (2): 762-771.
182. Lehr T, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008; 153 (1): 164-174.
183. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-1160.
184. Levy R, et al., editors. Metabolic Drug Interaction. Baltimore: Lipincott Williams & Wilkins, 2000.
185. Lim H-K, et al. A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun Mass Spec 2008; 22: 1295-1311.
186. Lim Y-P, Huang J-D. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 2008; 23 (1): 14-21.
187. Lin H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006; 23 (6): 1089-1116.
188. Lin J. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998; 26 (12): 1202-1212.
189. Lin J. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr Drug Metab 2008; 9 (5): 419-438.
190. Lin J, Lu A. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49 (4): 403-449.
191. Lin J, et al. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Topics Med Chem 2003; 3: 1125-1154.
192. Liu D, Hop C. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. J Pharm Biomed Analysis 2005; 37: 1-18.
193. Liu H, et al. Stereoselectivity in absorption of trans tramadol in rat intestine. Yao Xue Xue Bao 2003; 38 (12): 893-896.
194. Lock E, Schnellmann R. The effect of haloalkene cysteine conjugates on rat renal glutathione reductase and lipoyl dehydrogenase activities. Toxicol Appl Pharmacol 1990; 104 (1): 180-190.
195. Lu A, Wang R, Lin J. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003; 31 (4): 345-350.
196. Lu C, et al. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 2006a; 34 (9): 1600-1605.
197. Lu C, et al. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 2006b; 35 (1): 79-85.
198. Lu C, et al. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 2008a; 36 (7): 1255-1260.
199. Lu C, et al. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 2008b; 36 (7): 1261-1267.
200. Luo G, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30 (7): 795-804.
201. Luo G, et al. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004; 5: 483-505.
202. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Phys 2007; 76: 391-396.
203. Ma Q, Lu A. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. Curr Drug Metab 2008; 9: 374-383.
204. Ma X, et al. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 2007; 35 (2): 194-200.
205. Ma X, et al. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 2008; 36 (12): 2506-2512.
206. MacKichan J. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 1984; 9: 32-41.
207. MacKichan J. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989; 16 (2): 65-73.
208. Mahmood I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 2000; 40: 1439-1446.
209. Mahmood I, ed. Interspecies Pharmacokinetic Scaling. Rockville, MD: Pine House, 2005.
210. Mahmood I. Prediction of human drug clearance from animal data: application of the rule of exponents and " fu Corrected Intercept Method " (FCIM). J Pharm Sci 2006; 95 (8): 1810-1821.
211. Mahmood I, Green M, Fisher J. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 2003; 43: 692-697.
212. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Safety 2004; 27 (11): 773-797.
213. Marathe P, Rodrigues AD. In vivo animal models for investigating potential CYP3A-and Pgp-mediated drug-drug interactions. Curr Drug Metab 2006; 7 (7): 687-704.
214. Marchetti S, et al. Clinical relevance: drug-drug interaction, pharmacokinetics, pharmacodynamics, and toxicology. In: You G, Morris M, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition, John Wiley & Sons, 2007a, pp. 747-880.
215. Marchetti S, et al. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007b; 12: 927-941.
216. Masimirembwa C, Bredberg U, Andersson T. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003; 42 (6): 515-528.
217. Masubuchi N, Makino C, Murayama N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol 2007; 20: 455-464.
218. Matheny C, et al. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissue. Drug Metab Dispos 2004; 32 (9): 1008-1014.
219. Maurer T, Tabrizi-Fard M, Fung H-L. Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 2000; 89 (11): 1404-1414.
220. McConn D, Zhao Z. Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design. Curr Drug Metab 2004; 5: 141-146.
221. McElnay J, D'Arcy P. Protein binding displacement interactions and their clinical importance. Drugs 1983; 25: 495-513.
222. McLure J, Miners J, Birkett DJ. Nonspecific binding of drugs to human liver microso. Br J Clin Pharmacol 2000; 49: 453-461.
223. Meijerman I, Beijnen J, Schellens J. Herb-drug interactions in oncology: focus on mechanisms of induction. The Oncologist 2006; 11: 742-752.
224. Michalets E. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18 (1): 84-112.
225. Milo S, et al. Codeine and 6-acetylcodeine analgesia in mice. Cell Mol Neurobiol 2006; 26 (4-6): 1011-1019.
226. Miyazawa M, Sugie A, Shimada T. Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos 2003; 31 (8): 1049-1053.
227. Mohutsky M, et al. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm Res 2006; 23 (4): 654-662.
228. Mouly S, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72 (1): 1-9.
229. Munns A, et al. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 1997; 10 (9): 1049-1058.
230. Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008; 4 (7): 923-939.
231. Muruganandan S, Sinal C. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Nature 2008; 83 (6): 818-828.
232. Mutlib A, et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999; 27 (11): 1319-1333.
233. Mutlib A, et al. Disposition of glutathione conjugates in rats by a novel glutamic acid pathway: characterization of unique peptide conjugates by liquid chromatography/ mass spectrometry and liquid chromatography/NMR. J Pharmacol Exp Ther 2000; 294 (2): 735-745.
234. Nagilla R, et al. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 2006; 53: 106-116.
235. Naito S, et al. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals. J Toxicol Sci 2007; 32 (4): 329-341.
236. Naritomi Y, et al. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29 (10): 1316-1324.
237. Nassar A-EF, Lopez-Anaya A. Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discovery 2004; 7 (1): 126-136.
238. Nassar A-EF, Kamel A, Clairmont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discovery Tech 2004; 9 (23): 1020-1028.
239. Nassar A-EF, Lee D. Novel approach to performing metabolite identification in drug metabolism. J Chromatogr Sci 2007; 45: 113-119.
240. Neuberger J, Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 1989; 30 (4): 515-519.
241. Nielsen K, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277 (3): 1659-1664.
242. Niwa T, et al. Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A. Biol Pharm Bull 2000; 23 (4): 498-501.
243. Noe J, et al. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007; 35 (8): 1308-1314.
244. Oates J. The science of drug therapy. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006, pp. 117-136.
245. Obach R. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 1996; 24 (10): 1047-1049.
246. Obach R. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 1997; 25 (12): 1359-1369.
247. Obach R. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27 (11): 1350-1359.
248. Obach R. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correl. Drug Metab Dispos 2000a; 28 (9): 1069-1076.
249. Obach R. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000b; 294 (1): 88-95.
250. Obach R. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discovery Dev 2001; 4 (1): 36-44.
251. Obach R, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283 (1): 46-58.
252. Obach R, et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 582-592.
253. Obach R, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316 (1): 336-348.
254. Obach R, Walsky R, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35 (2): 246-255.
255. Obach R, et al. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem Res Toxicol 2008b; 21 (9): 1890-1896.
256. Obach R, et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 2008a; 21: 1814-1822.
257. Ohmori S, et al. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 1993; 16 (6): 517-575.
258. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46 (8): 681-696.
259. Okumura K, et al. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997; 61 (5): 509-517.
260. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discovery 2003; 2 (2): 132-139.
261. Otton S, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53 (4): 401-409.
262. Pal D, Mitra A. MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006; 1: 323-339.
263. Pang S. Safety testing of metabolites: expectations and outcomes. Chemico-Biol Interactions 2009; 179 (1): 45-59.
264. Pang S, Sun H, Liu S. Interplay of drug transporters and enzymes on hepatic drug disposition. In: You G, Morris M, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, NJ: John Wiley & Sons, 2007, pp. 709-745.
265. Park K, et al. Selection of new chemical entities with decreased potential for adverse drug reactions. Eur J Pharmacol 2006; 549: 1-8.
266. Parker A, Houston J. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 2008; 36 (7): 1375-1384.
267. Parkinson A. Biotransformation of Xenobiotics. In: Klaassen CD, editor. Casarett and Doull's Toxicology. McGraw-Hill, 2001, pp. 134-224.
268. Patel N, et al. Glutathione-dependent biosynthesis and bioactivation of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-l-cysteine, the glutathione and cysteine S-conjugates of dichloroacetylene, in rat tissues and subcellular fractions. Drug Metab Dispos 1994; 22 (1): 143-147.
269. Pearce RE, Rodrigues AD, Goldstein JA. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-816.
270. Pelkonen O, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82 (10): 667-715.
271. Penning T, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40 (9): 1347-1365.
272. Pirmohamed M, et al. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992; 43 (8): 1675-1682.
273. Polasek T, Miners JO. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 2007; 3 (3): 321-329.
274. Ponsoda X, et al. Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality? Altern Lab Animals 2004; 32: 101-110.
275. Pottenger L, et al. The relative bioavailability and metabolism of bisphenol A in rats is dependent upon the route of administration. Toxicol Sci 2000; 54 (1): 3-18.
276. Powis G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev 1983; 14 (6): 1145-1163.
277. Prakash C, Shaffer C, Nedderman A. Analytical strategies for identifying drug metabolites. Mass Spec Rev 2007; 26: 340-369.
278. Proctor N, Tucker G, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Proctor NJ, Tucker. Xenobiotica 2004; 34 (2): 151-178.
279. Prueksaritanont T, Lin J, Ballie T. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol 2006; 217: 143-152.
280. Puga A, Ma C, Marlowe J. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 2009; 77 (4): 713-722.
281. Raj H, et al. Chemoprevention of benzene-induced bone marrow and pulmonary genotoxicity. Teratogenesis Carcinogenesis and Mutagenesis 2001; 21 (2): 181-187.
282. Ramadan Z, Wrang M, Tipton K. Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. Neurochem Res 2007; 32 (10): 1783-1790.
283. Rashed M, Streeter A, Nelson S. Investigations of the N-hydroxylation of 3 '-hydroxyacetanilide, a non-hepatotoxic positional isomer of acetaminophen. Drug Metab Dispos 1989; 17 (4): 355-359.
284. Reddy A, et al. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal 2005; 37: 319-326.
285. Rendic S, Di Carlo F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29 (1/2): 413-580.
286. Riley R, Martin I, Cooper A. The influence of DMPK as an integrated partner in modern drug discovery. Curr Drug Metab 2002; 3: 527-550.
287. Riley R, McGinnity D, Austin R. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005; 33 (9): 1304-1311.
288. Riley R, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007; 3 (1): 51-66.
289. Roberts P, Kitteringham N, Park B. Elucidation of the structural requirements for the bioactivation of mianserin in vitro. J Pharm Pharmacol 1993; 45 (7): 663-675.
290. Rodrigues AD, Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 465-480.
291. Rodrigues AD, editor. Drug-Drug Interactions, 2nd edition. Drugs and Pharmaceutical Sciences, Vol. 179. New York: Informa Healthcare, 2008.
292. Rodrigues AD, Rushmore T. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002; 3: 289-309.
293. Rolan P. Plasma protein binding displacement interactions -why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37 (2): 125-128.
294. Rosenblum S, et al. Discovery of 1-(4-fluorophenyl)-(3 R)-[3-(4-fluorophenyl)-(3 S)-hydroxypropyl]-(4 S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 1998; 41 (6): 973-980.
295. Rostami-Hodjegan A, Tucker G. Simulation and prediction of in vivo drug metabolism in human populations from in vitro. Nature Rev Drug Discov 2007; 6 (2): 140-148.
296. Rydberg T, et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997; 43 (4): 373-381.
297. Safety Testing of Drug Metabolites, FDA, editor. http://www.fda.gov/CDER/GUIDANCE/6897fnl.pdf.2008.
298. Sahi J, et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin -A receptor antagonist CI-1034. Chemico-Biol Interactions 2006; 159 (2): 156-168.
299. Sakaguchi K, et al. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 2004; 424: 219-225.
300. Satoh T. Genetic polymorphism in drug metabolism and toxicity: linking animal research and risk assessment in man. AATEX 2007; 14: 443-445.
301. Schaefer W. Reaction of primary and secondary amines to form carbamic acid glucuronides. Curr Drug Metab 2006; 7/8: 873-881.
302. Scholz K, et al. Rapid detection and identification of N-acetyl-l-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced production scans on a linear ion trap mass spectrometer. J Am Soc Mass Spectrom 2005; 16: 1976-1984.
303. Sellers E. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 1979; 18: 225-227.
304. Shet M, et al. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 1997; 25 (11): 1298-1303.
305. Shiran M, et al. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 2006; 36 (7): 567-580.
306. Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discovery Dev 2005; 8 (1): 66-77.
307. Siebert G, et al. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther 2004; 308 (1): 228-235.
308. Silverman R, edition. The Organic Chemistry of Drug Design and Drug Action, 2nd edition. New York: Elsevier, 2004.
309. Sinha V, et al. Predicting oral clearance in humans: how close can we get with allometry? Clin Pharmacokin 2008; 47 (1): 35-45.
310. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 2008; 10 (2): 391-400.
311. Smith D, Obach R. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 2005; 33 (10): 1409-1417.
312. Smith D, Obach R. Metabolites and safety: What are the concerns, and how should we address them? Chem Res Toxicol 2006; 19: 1570-1579.
313. Smith D, van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr Opin in Chem Biol 1999; 3: 373-378.
314. Smith D, Jones B, Walker D. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996; 16 (3): 243-246.
315. Smith D, et al. Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. Chemico-Biol Interactions 2009; 179 (1): 60-67.
316. Smith K, et al. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 2003; 16 (2): 123-128.
317. Soars M, et al. The pivotal role of hepatocytes in drug discovery. Chemico-Biol Interactions 2007a; 168: 2-15.
318. Soars M, et al. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 2007b; 35 (6): 859-865.
319. Soglia J, et al. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal 2004; 36: 105-116.
320. Soglia J, et al. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem Res Toxicol 2006; 19: 480-490.
321. Staack R, Hopfgartner G. New analytical strategies in studying drug metabolism. Anal Bioanal Chem 2007; 388: 1365-1380.
322. Stella V, et al. editors. Prodrugs:Challenges and Rewards, Part 2. New York: Springer, 2007.
323. Stohs S, Al-Turk W, Hassing J. Age 1980; 3 (4): 88-92.
324. Stoner C, et al. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int J Pharmaceutics 2004; 269: 241-249.
325. Stratford RJ, et al. Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication. J Pharm Sci 1999; 88 (8): 747-753.
326. Suzuki K, Kamimura H. Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. Biol Pharm Bull 2007; 30 (8): 1580-1585.
327. Szakacs G, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today 2008; 13 (9/10): 379-393.
328. Tahara H, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 2005; 315 (1): 337-345.
329. Tahara H, et al. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 2006; 316 (3): 1187-1194.
330. Takakusa H, et al. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 2008; 36 (9): 1770-1779.
331. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006; 109 (1-2): 137-161.
332. Takeda S, et al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 2006; 34 (8): 1277-1282.
333. Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2007; 3 (3): 407-420.
334. Tang W, Abbott F. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. Drug Metab Dispos 1997; 25 (2): 219-227.
335. Tassaneeyakul W, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47 (10): 1767-1776.
336. Thompson C, Kinter M, Macdonald T. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9 (8): 1225-1229.
337. Thompson T, Optimization of metabolic stability as a goal of modern drug design. Med Res Rev 2001; 21 (5): 412-449.
338. Thornton-Manning J, et al. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. J Pharmacol Exp Ther 1996; 276 (1): 21-29.
339. Thummel KE, Shen D, Isoherranen N. Role of the gut mucosa in metabolically based drug-drug interactions. In: Rodrigues AD, editor. Drug-Drug Interactions, Informa Healthcare, 2008, pp. 471-513.
340. Timbrell J, editor. Principles of Biochemical Toxicology. London: Taylor & Francis, 1982.
341. Timchalk C, Smith F, Bartels M. Route-dependent comparative metabolism of [14C] toluene 2,4-diisocyanate and [14C]toluene 2,4-diamine in Fischer 344 rats. Toxicol Appl Pharmacol 1994; 124: 181-190.
342. Tirona R, et al. The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9 (2): 220-224.
343. Tomlinson E, et al. Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol 1997; 62 (4): 345-352.
344. Townsend D, et al. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin. Drug Metab Dispos 2003; 31 (6): 705-713.
345. Tracy T, Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R D 2006; 7 (6): 349-363.
346. Tracy T, Hummel M. Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab Rev 2004; 36 (2): 231-242.
347. Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discovery Dev 2001; 4 (1): 55-59.
348. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discovery Tech 2003; 8 (18): 832-837.
349. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab Rev 2006; 38: 745-753.
350. Uetrecht J, et al. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem Res Toxicol 1995; 8 (2): 226-233.
351. Urquhart B, Tirona R, Kim R. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007; 47 (5): 566-578.
352. Uttamsingh V, et al. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005; 33 (11): 1723-1728.
353. Van L, et al. Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. J Pharm Sci 2009; 98 (2): 763-771.
354. van de Steeg E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human OATP1B1 (SLCO1B1). Drug Metab Dispos 2009; 37 (2): 277-281.
355. van Voorhis W, et al. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother 2007; 51 (10): 3659-3671.
356. Venkatakrishnan K, Obach R. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005; 33 (6): 845-854.
357. Venkatakrishnan K, Obach R. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007; 8: 449-462.
358. Venkatakrishnan K, et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28 (12): 1493-1504.
359. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149-1179.
360. Venkatakrishnan K, et al. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003; 4: 423-459.
361. Veronese M, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43 (8): 831-839.
362. Victor F, et al. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem 1997; 40 (10): 1511-1518.
363. Voorman R, et al. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998; 287 (1): 381-388.
364. Von Moltke LL, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999; 48: 89-97.
365. Von Moltke LL, et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259-261.
366. Walgren J, Mitchell M, Thompson D. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Critical Rev Toxicol 2005; 35: 325-361.
367. Walle T, Wen X, Walle U. Improving metabolic stability of cancer chemoprotective polyphenols. Expert Opin Drug Metab Toxicol 2007; 3 (3): 379-388.
368. Wang H, LeCluyse E. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003; 42 (15): 1331-1357.
369. Wang S, et al. Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3. Drug Metab Dispos 2003; 31 (6): 773-775.
370. Wang X, Morris M. Diet/nutrient interactions with drug transporters. In You G, Morris M, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition, Hoboken, NJ: John Wiley & Sons, 2007, pp. 665-708.
371. Weaver R. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001; 31 (8/9): 499-538.
372. Wauthier V, Verbeek R, Calderon P. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 2007; 14: 745-757.
373. Weinkers L, Heath T. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Rev 2005; 4: 825-833.
374. Wilkinson G. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983; 14 (3): 427-465.
375. Wilkinson G. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39 (1): 1-47.
376. Wilkinson G, Shand D. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacokinet Ther 1975; 18 (4): 377-390.
377. Williams D, et al. Induction of metabolism-dependent and-independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58 (1): 207-216.
378. Williams J, et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002; 30 (11): 1266-1273.
379. Williams J, et al. In vitro ADME phenotyping in drug discovery: current challenges and future solutions. Curr Opin in Drug Discovery Dev 2005; 8 (1): 78-88.
380. Williams J, et al. PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 2008; 48: 849-889.
381. Xu C, Li Y-T, Kong A-N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005; 28 (3): 249-268.
382. Xu S, et al. Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab Dispos 2005; 33 (1): 121-130.
383. Yamashiro W, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34 (7): 1247-1254.
384. Yamazaki H, Shimada T. Arch Biochem Biophys 1993; 346 (1): 161-169.
385. Yang J, et al. Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 2007; 31: 232-241.
386. Yan Z, Caldwell C, Maher N. Unbiased high-throughput screening of reactive metabolites on the linear ion trap mass spectrometer using polarity switch and mass tag triggered data-dependent acquisition. Anal Chem 2008; 80: 6410-6422.
387. Yao C, Levy R. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002; 91 (9): 1923-1935.
388. Yasumori T, et al. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther 1993; 264 (1): 89-94.
389. Yeh K, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39 (11 (2)): 25-38.
390. Yengi L, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharm Res 2007; 24 (5): 842-858.
391. Yoshihara S, Harada K, Ohta S. Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in perfused rat liver: involvement of hepatic aldehyde oxidase as a detoxification enzyme. Drug Metab Dispos 2000; 28 (5): 538-543.
392. You G, Morris M, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Wiley Series in Drug Discovery and Development, Wang B, series editor. Hoboken, NJ: John Wiley & Sons, 2007.
393. Youdim K, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008; 65 (5): 680-692.
394. Zhang H, et al. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metab Dispos 2007a; 35 (5): 795-805.
395. Zhang H, et al. Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 2007b; 3 (5): 667-687.
396. Zhang K, et al. Metabolism of A dopamine D(4)-selective antagonist in rat, monkey, and humans: formation of A novel mercapturic acid adduct. Drug Metab Dispos 2000; 28 (6): 633-642.
397. Zhang L, et al. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008; 38 (7/8): 709-724.
398. Zhao P, Kalhorn T, Slattery J. Hepatology 2003; 36 (2): 326-335.
399. Zhao P, The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 2008; 4 (2): 151-164.
400. Zhou C, et al. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004a; 32 (10): 1075-1082.
401. Zhou S, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004b; 18 (2): 262-276.
402. Zhou S, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15 (20): 1981-2039.
403. Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9 (4): 310-322.
404. Zhou S-F, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004c; 5: 415-442.